CDKN2A and Miyoshi myopathy: Novel substances targeting pathways in which tumor suppressor genes are implicated in MM etiology, such as BAP1, NF2 or CDKN2A encoding BRCA1-associated protein 1, neurofibromin 2 (merlin) and cyclin-dependent kinase inhibitor 2A, respectively, together with inhibitors of CSC survival (e.g., focal adhesion kinase (FAK) inhibitors) are other promising avenues towards novel MM treatments (for more details, see [2,4,12]).